Fiorenzo Villani Purchases 7,000 Shares of Portage Biotech (NASDAQ:ALP) Stock

Portage Biotech Inc. (NASDAQ:ALP) insider Fiorenzo Villani purchased 7,000 shares of the firm’s stock in a transaction on Wednesday, September 9th. The stock was acquired at an average cost of $5.07 per share, for a total transaction of $35,490.00. Following the completion of the purchase, the insider owned 22,219 shares in the company, valued at $112,650.33. The trade was a 46.00% increase in their position. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website.

Portage Biotech Stock Down 3.8%

ALP opened at $4.00 on Wednesday. Portage Biotech Inc. has a 12 month low of $3.20 and a 12 month high of $690.00. The business has a 50-day moving average of $10.28 and a two-hundred day moving average of $14.62. The company has a debt-to-equity ratio of 0.01, a current ratio of 0.31 and a quick ratio of 0.31. The stock has a market capitalization of $6.20 million, a price-to-earnings ratio of -0.01 and a beta of 0.54.

Portage Biotech (NASDAQ:ALP) last announced its quarterly earnings data on Thursday, July 16th. The company reported $23.75 earnings per share for the quarter. The company had revenue of $0.05 million for the quarter. On average, research analysts expect that Portage Biotech Inc. will post -14 earnings per share for the current year.

Wall Street Analysts Forecast Growth

ALP has been the topic of a number of research analyst reports. Weiss Ratings reiterated a “sell (e+)” rating on shares of Portage Biotech in a report on Friday, July 24th. HC Wainwright initiated coverage on Portage Biotech in a report on Monday, August 17th. They set a “neutral” rating and a $12.50 price objective for the company. Zacks Research upgraded Portage Biotech to a “hold” rating in a report on Tuesday, August 18th. Finally, Wall Street Zen raised Portage Biotech to a “hold” rating in a research report on Saturday. Two analysts have rated the stock with a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat, Portage Biotech has a consensus rating of “Reduce” and a consensus price target of $12.50.

About Portage Biotech

Portage Biotech (NASDAQ:ATON) is a biotechnology company focused on acquiring, developing and advancing therapeutic candidates and platform technologies. The company concentrates its development efforts primarily in areas such as oncology, immunology/inflammation and infectious disease, seeking to move programs from discovery and preclinical stages into clinical development through subsidiary companies and collaborative arrangements.

Portage structures its operations to support a diversified pipeline, advancing both small molecules and biologics by funding preclinical research, conducting clinical trials, and managing regulatory interactions.